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Abstract 
Tyrosine and aurora kinases are important effectors in signal transduction pathways that are often 
involved in aberrant cancer cell growth. Tyrosine (TKI) and aurora (AKI) kinase inhibitors are anti-cancer 
agents specifically designed to target such signaling pathways through TKI/AKI binding to the ATP-binding 
pocket of kinases thereby leading to diminished kinase activity. Some TKIs have been identified as inhibitors 
of ATP-binding cassette (ABC) transporters such as P-glycoprotein and breast cancer resistance protein 
(BCRP), which are commonly upregulated in malignant cells. TKI/AKIs have been investigated as ABC 
transporter inhibitors in order to facilitate the accumulation of concomitantly administered chemo-
therapeutics within cancer cells. However, ABC transporters are prominently expressed in the liver and 
other eliminating organs, and their inhibition has been linked to intracellular accumulation of drugs, 
altered disposition, and toxicity. The potential for TKIs/AKIs to inhibit other important hepatic efflux 
transporters, particularly multidrug resistance-associated proteins (MRPs), remains unknown. The aim of 
the current study was to compare the inhibitory potency of 20 selected TKI/AKIs against MRP4 and BCRP 
through the use of inverted membrane vesicle assays. Relative IC50 values were estimated by determining 
TKI/AKI inhibition of MRP4-mediated [
3
H]-dehydroepiandrosterone sulfate uptake and BCRP-mediated [
3
H]-
estrone sulfate uptake. To provide insight to the clinical relevance of TKI/AKI inhibition of ABC efflux 
transporters, the ratio of the steady-state maximum total plasma concentration (Css) to the IC50 for each 
compound was calculated with Css/IC50 ratio >0.1 deemed potentially clinically relevant. Such analysis 
identified several potentially clinically relevant inhibitors of MRP4: alisertib, danusertib, erlotinib, lapatinib, 
neratinib, nilotinib, pazopanib, sorafenib, and tozasertib. The potentially clinically relevant inhibition of 
BCRP was much more extensive and included alisertib, barasertib, danusertib, enzastaurin, erlotinib, 
gefitinib, imatinib, neratinib, nilotinib, pazopanib, selumetinib, sorafenib, sunitinib, tozasertib, and 
vandetanib. These findings indicate the significant potential for TKI/AKIs to inhibit multiple ABC efflux 
transporters. The resulting inhibition data could provide insight regarding the clinical interpretation of 
pharmacokinetic/pharmacodynamic outcomes when TKI/AKIs are administered concomitantly with 
additional chemotherapeutic agents. 
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Introduction 
Small molecule kinase inhibitors have revolutionized the field of oncology by facilitating the targeting of 
specific kinases, which have been found to be over-expressed and/or mutated in specific tumor types. Such 
targeting has enabled a more directed, individualistic treatment regimen for many patients [1-4]. These 
small molecule kinase inhibitors have been designed primarily to target specific receptor tyrosine kinases, 
namely the epidermal growth factor receptor (EGFR and HER2), vascular endothelial growth factor 
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and the BCR/ABL (breakpoint cluster 
region/Abelson) fusion protein; however, some off-target inhibition of intracellular kinases can occur. 
Receptor tyrosine kinases are important mediators of intracellular signaling cascades [4-6]. Specifically, 
upon binding of ligand to the receptor tyrosine kinase, autocatalytic phosphorylation events spark the 
propagation of one or more signaling cascades ultimately leading to transcription of genes. Aberrant 
regulation of receptor tyrosine kinases can result in amplification of genes related to proliferation, 
apoptosis, and differentiation, and thus enable cancer cell growth and metastasis [3, 6]. Aurora kinases are 
different from receptor tyrosine kinases in that they are primarily active during mitosis, but also have been 
found to be upregulated in many tumor types [7, 8]. As such, several small molecule inhibitors have been 
designed in an effort to mitigate the activity of aurora kinases during cancer cell growth. Though kinase 
inhibitors are designed with a particular target in mind, cross-reactivity with off-target kinases can occur in 
nonmalignant cells, which may increase the potential for off-target, potentially toxic effects [4, 9]. 
TKIs and AKIs exert their effects by acting as ATP-mimics and binding to the ATP-binding pocket of 
kinases to decrease the kinase catalytic activity [2]. In recent years, TKIs have been identified as inhibitors 
of several ATP-binding cassette (ABC) efflux transporters that are commonly upregulated in cancer cells 
including P-glycoprotein (multidrug resistance protein 1), breast cancer resistance protein (BCRP), and 
multidrug resistance-associated protein (MRP) 1 [10-18]. ABC efflux transporters consist of a large family of 
membrane-spanning proteins involved in the active extrusion of substrates such as endogenous molecules, 
drugs, and drug metabolites from the cell through hydrolysis of ATP [19-21]. ABC efflux transporters are 
expressed prominently in eliminating organs such as the liver and kidney, and thus can play a significant 
role in the overall disposition of a drug within the body [19]. Upregulation of ABC efflux transporters in 
cancer cells confers chemoresistance, and imparts a greater ability of the cell to limit exposure to, and 
diminish the effects of, chemotherapeutic agents [12, 22, 23]. The upregulation of ABC transporters during 
chemoresistance has made them an attractive target in overcoming the clinical difficulty of maintaining 
intracellular exposure to chemotherapeutics. Due to their ability to inhibit ABC transporters commonly 
upregulated in cancer cells, kinase inhibitors recently have been investigated for their capability to reverse 
chemoresistance. In particular, BCRP can confer resistance to gefitinib, but in contrast also is inhibited by 
gefitinib, vandetanib, and neratinib [18]. Similarly, it has been shown that sunitinib is an inhibitor of BCRP 
and can reverse chemoresistance to co-administered chemotherapeutics in BCRP over-expressing cells 
[16]. Others have shown that dasatinib, nilotinib, and imatinib are competitive inhibitors of P-glycoprotein 
and BCRP, meaning that they are substrates at low concentrations, while they inhibit transport function at 
high concentrations [24]. Although these data indicate the potential for kinase inhibitors to be used as 
tools to overcome chemoresistance through ABC efflux transporter inhibition in vitro, several clinical trials 
employing kinase inhibitors for mitigation of chemoresistance have been unable to definitively 
demonstrate improvements in progression free survival and/or overall survival of patients [25-28]. 
Studies seeking to utilize kinase inhibitors for mitigation of chemoresistance though inhibition of 
specific ABC efflux transporters that are upregulated in cancer cells often fail to address a key 
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complication: off-target inhibition of ABC efflux transporters in eliminating organs such as liver, kidney, and 
intestine. Several MRPs including MRP2, MRP3, and MRP4 are differentially localized to the apical and 
basolateral membranes of hepatocytes, enterocytes, and proximal tubule cells, which enables them to 
direct the disposition of some chemotherapeutics [19, 20]. For example, MRP2 is localized to the apical 
membrane of hepatocytes while MRP3 is situated at the basolateral membrane. MRP2 and MRP3 share 
substrate specificity yet extrude drugs and drug metabolites into the bile and systemic circulation, 
respectively [19]. Inhibition of MRP2 can shift the hepatobiliary disposition of a drug from bile, and 
subsequent elimination in feces, to the sinusoidal blood resulting in greater systemic exposure. Similar to 
MRP3, MRP4 resides on the basolateral membrane of hepatocytes, while BCRP, like MRP2, is localized to 
the apical membrane with each differentially extruding drugs and metabolites into the systemic circulation 
and bile, respectively. MRP4 transports nucleosides, Phase II conjugation products, and conjugated bile 
acids [20, 29]. Inhibition of MRP4-mediated transport has been associated with an increased risk of 
cholestatic potential, particularly among compounds that do not inhibit the bile salt export pump (BSEP) 
[29]. Similarities in the chemical properties of MRP4 inhibitors and BSEP inhibitors have been identified 
[30]. Collectively, data suggest that MRP4 inhibition may serve as a confounding factor in BSEP-mediated 
drug-induced liver injury or, in some cases, lead to drug-induced liver injury in the absence of BSEP 
inhibition. Thus, inhibition of one or more ABC efflux transporters can significantly affect the disposition of 
a co-administered drug, and in some cases, may impact the risk of hepatotoxicity. Knowledge of the 
inhibitory potency of TKIs and AKIs for multiple ABC efflux transporters, not limited to those upregulated in 
cancer cells, is critically important to predict the pharmacokinetic and pharmacodynamic outcomes and 
potential for hepatotoxicity of TKI/AKIs and co-administered chemotherapeutics. The purpose of the 
current study was to compare the inhibitory potency of 20 TKIs and AKIs (see Table 1 for selected 
compounds) against the ABC efflux transporters MRP4 and BCRP using inverted membrane vesicle assays. 
Additionally, half maximal inhibitory concentration (IC50) data were leveraged against reported steady state 
concentration (CSS) values to provide insight to the clinical relevance of TKI/AKI inhibition of MRP4- and 
BCRP-mediated transport function. 
Table 1. Selected Tyrosine (TKI) and Aurora (AKI) Kinase Inhibitors. Twenty TKI/AKIs were selected for analysis of 
their potential to inhibit MRP4- and BCRP-mediated transport. TKI/AKIs are categorized by primary kinase target. 
EGFR, epidermal growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived 
growth factor receptor; BCR/ABL, Breakpoint cluster region/Abelson fusion protein. 
Primary Target Inhibitors 
EGFR erlotinib, gefitinib, lapatinib, neratinib, vandetanib 
VEGFR & PDGFR axitinib, pazopanib, sorafenib, sunitinib 
BCR/ABL bosutinib, dasatinib, imatinib, nilotinib 
Miscellaneous crizotinib (anaplastic lymphoma kinase), enzastaurin (protein kinase C isoforms), selumetinib 
(mitogen-activated protein kinase 1) 




Cell culture supplies were obtained from Gibco (Life Technologies, Grand Island, NY), and hygromycin B 
from Roche Life Sciences (Indianapolis, IN). Microscint-20, [3H]-dehydroepiandrosterone-sulfate (DHEAS; 
70.5 Ci/mmol) and [3H]-estrone sulfate (E1S; 45 Ci/mmol) were purchased from Perkin Elmer Life and 
Analytical Sciences (Waltham, MA). DMSO (dimethylsulfoxide) was obtained from Fisher Scientific 
(Fairlawn, NH). Compounds were purchased from Selleckchem (Houston, TX) or Cayman Chemical (Ann 
Arbor, MI). 
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Cell Culture and Membrane Vesicle Preparation 
HEK293T cells stably overexpressing MRP4 (HEK-MRP4), HEK293T cells transfected with empty vector 
(HEK-MOCK), MDCKII cells stably overexpressing BCRP (MDCKII-BCRP), and untransfected MDCKII cells 
were cultured in DMEM supplemented with 10 % FBS as previously described [29, 31]. MRP4 or BCRP over-
expression was maintained by antibiotic selection with hygromycin B [29]. Cells were grown to ~85-95 % 
confluence before membrane vesicle preparation. Membrane vesicles were prepared as previously 
described [31-34]. Vesicles were validated for maximal activity and used in transport studies within 1-2 
weeks of preparation. 
Western Blot Analysis of Transporter Expression 
Transporter over-expression was verified in control and transporter over-expressing membrane vesicles 
via western blot analysis. Lysates of membrane vesicles (15 μg/well) were prepared in tris-glycine SDS 
sample buffer (Life Technologies) and separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
using 4-12 % tris-glycine gels (Life Technologies). Proteins separated by SDS-PAGE were transferred to 
polyvinylidene difluoride (PVDF) membranes overnight. Protein levels on membranes were determined by 
incubation with antibodies directed against MRP4 (M4I-10, generously provided by George L. Scheffer, 
Amsterdam, The Netherlands) or BCRP (BXP-21, Kamiya Biomedical Company). 
Membrane Vesicle Transport Assay 
TKI- and AKI-mediated inhibition of transport function was investigated in membrane vesicles so as to 
study the function of a single transporter in isolation without confounding variables such as cellular uptake 
or protein binding. To confirm transport based on previously developed assays, transport of [3H]- DHEAS (2 
µM, 0.7 µCi/mL) by MRP4 or [3H]- E1S (1 µM; 0.4 µCi/mL) by BCRP was measured over time via incubation 
of control (HEK-MOCK or MDCKII) and transporter over-expressing (HEK-MRP4 or MDCKII-BCRP) 
membrane vesicles in tris-sucrose buffer (50 mM tris/HCl and 250 mM sucrose, pH 7.4) in the presence or 
absence of an ATP-regenerating system (4 mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, and 0.1 
mg/mL creatine kinase). Transporter substrate concentrations were selected based on Km values [29, 34]. 
AMP was replaced with ATP for incubations conducted in the absence of an ATP-regenerating system. The 
difference between uptake with ATP versus AMP was used to determine the ATP-dependent uptake of 
[3H]-DHEAS and [3H]-E1S in MRP4 and BCRP membrane vesicles, respectively. For transport inhibition 
assays, 20 different TKI- or AKI-test compounds (alisertib, axitinib, barasertib, bosutinib, crizotinib, 
danusertib, dasatinib, enzastaurin, erlotinib, gefitinib, imatinib, lapatinib, neratinib, nilotinib, pazopanib, 
selumetinib, sorafenib, sunitinib, tozasertib, or vandetanib) solubilized in DMSO (1 % DMSO final reaction 
concentration) were added in separate experiments to the reaction mixture containing control or 
transporter over-expressing membrane vesicles in tris-sucrose buffer with the ATP-regenerating system. 
Test compounds were examined at a concentration range of 0.316-100 μM. For potent BCRP inhibitors, the 
concentration range was reduced to 0.00316 μM. For control samples, identical concentrations of the 
solvent (1 % DMSO) were used. All uptake studies were performed at 37 °C. Uptake was stopped by 
addition of ice cold tris-sucrose buffer followed by rapid vacuum filtration through glass fiber 96-well plates 
pre-soaked in tris-sucrose buffer (BCRP reactions) or tris-sucrose buffer with 3 mM glutathione and 10 mM 
dithiothreitol (MRP4). Microscint-20 (75 μL) was added to each well and the plate was allowed to rotate on 
an orbital shaker for 15 minutes. Radioactivity was quantified by liquid scintillation counting in a TopCount 
NXT instrument (Perkin Elmer). Incubations with test compounds were completed in at least three 
independent experiments with no replicates in individual experiments. Positive control inhibitors (MK571 
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for MRP4; sulfasalazine and promethazine for BCRP) were included in each individual experiment for 
quality control. 
Data Analysis and Statistics 
Substrate uptake into vesicles was calculated as pmol/mg protein/min before conversion to percent of 
control inhibition. Inhibition by TKI/AKIs as a percentage of control was calculated as the difference 
between substrate uptake in control and transporter-overexpressing membrane vesicles compared to 
vehicle-treated membrane vesicles (mean ± standard deviation, SD). Dose-response IC50 curves were fit via 
nonlinear regression analysis according to the four-parameter logistic model (4PL) with the bottom 
constraint set to >0 using GraphPad Prism 5. For analysis of potential clinical relevance of transporter 
inhibition, steady-state total plasma Css values for each TKI/AKI were extracted from Micromedex and 
manufacturer package inserts. 
Results and Discussion 
MRP4 over-expression was confirmed in HEK-MRP4 membrane vesicles, and was significantly higher 
than HEK-MOCK membrane vesicles (Figure 1A). The time- and ATP-dependent uptake of [
3
H]-DHEAS in 
HEK-MRP4 vesicles was linear up to 10 minutes (Figure 1A), similar to previous studies [29].  [3H]-DHEAS 
uptake in HEK-MRP4 vesicles was at least 75-fold greater than in HEK-MOCK vesicles. An incubation time of 
3.5 minutes was chosen for experiments with HEK-MRP4 vesicles to evaluate the inhibition potential of 
test compounds, similar to previous studies [29]. The pan-MRP inhibitor MK571 was assessed across a 
concentration range of 0.316-100 μM. MK571 produced a prototypical dose-response curve ranging from 
nearly full activity to complete inhibition (Figure 1B) with an IC50 value of 2.04 μM (95 % confidence 
interval: 1.31-3.19 μM). Morgan, et al. previously reported an IC50 value of 6 µM for MK571-mediated 
inhibition of 
3
H-estradiol-17β-D-glucuronide uptake in MRP4 membrane vesicles derived from Sf9 cells 
[35]. MK571 was included as a positive control with all subsequent test compound experiments for quality 
assurance of the MRP4 vesicle assay. 
 
Figure 1. Characterization of the MRP4 Membrane Vesicle Assay. (A) MRP4 expression in HEK-MOCK and 
HEK-MRP4 cells. Also shown is ATP-dependent, time-dependent uptake of 2 μM [
3
H]-dehydroepiandrosterone 
(DHEAS) in membrane vesicles. Data are presented as mean ± SD, n=3 independent experiments. (B) Dose-
response IC50 curve of the MRP4 positive control inhibitor MK571 (3.5 min incubation). Data are presented as 
mean % of control uptake ± SD, n=7 independent experiments. 
The inhibition potential of 20 TKI/AKIs was assessed in control and MRP4 over-expressing membrane 
vesicles. Dose-response curves of TKIs are shown in Figure 2. Of the 16 TKIs examined, 6 exhibited IC50 
values <10 μM (Table 2), namely, the EGFR inhibitors erlotinib, gefitinib, lapatinib and neratinib; the VEGFR 
& PDGFR inhibitor sorafenib; and the BCR/ABL inhibitor nilotinib. Others have reported the inhibitory 
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potency of some TKIs against MRP4-mediated transport, particularly dasatinib, gefitinib, imatinib, lapatinib, 
neratinib, pazopanib, and sunitinib [35]. We found a similar IC50 for gefinitib inhibition of MRP4 (4.48 μM) 
to that of Morgan, et al. (4.6 μM), and a somewhat comparable IC50 for dasatanib (18.03 μM in the present 
study versus 27.3 μM). However, the IC50 values for the remaining TKIs evaluated by Morgan, et al. were 
notably different, which may reflect differences in the experimental conditions such as the specific 
transporter substrate and range of inhibitor concentrations selected for investigation (e.g. extrapolation of 
an IC50 value beyond the tested concentrations) [35, 36]. The majority of the potent MRP4 inhibitors fell 
within the EGFR TKI class with only one potent inhibitor each in the dual VEGFR & PDGFR and the BCR/ABL 
classes. Four AKIs were tested for their potential to inhibit MRP4 (Figure 3). Two AKIs, danusertib and 
tozasertib, produced IC50 values <10 μM (Table 2). In particular, tozasertib exhibited comparable inhibitory 
potency to MK571 (1.87 ± 0.81 μM versus 2.04 μM, respectively). In total, eight of the 20 TKI/AKIs assessed 
were identified as potent inhibitors (IC50 ≤ 10 μM) of MRP4. 
 
Figure 2. MRP4 Inhibition by Tyrosine Kinase Inhibitors. Inhibition of MRP4-mediated [
3
H]-DHEAS (2 μM; 3.5 
min) uptake across an inhibitor concentration range of 0.316-100 μM by EGFR, VEGFR/PDGFR, BCR/ABL 
inhibitors, and inhibitors with miscellaneous targets is shown. Data are presented as mean % of control 
uptake ± SD, n=3-6 independent experiments. 
BCRP over-expression in MDCKII-BCRP membrane vesicles was determined via western blot analysis and 
compared to control MDCKII vesicles (Figure 4A). BCRP over-expression was confirmed to be substantially 
greater in MDCKII-BCRP vesicles. To establish the BCRP membrane vesicle transport assay, the time- and 
ATP-dependent uptake of [3H]-E1S was measured in MDCKII and MDCKII-BCRP vesicles (Figure 4A). The 
uptake of [3H]-E1S was linear up to 1.5 minutes and appeared to saturate by 3 minutes. An incubation time 
of 1.5 minutes was chosen for subsequent assessment of potential BCRP inhibitors. There was at least a 35-
fold increase in [3H]-E1S uptake in MDCKII-BCRP versus MDCKII vesicles. Several compounds ascribed as 
BCRP inhibitors were assessed for their potential as positive controls in the membrane vesicle inhibition 
assay. Sulfasalazine and promethazine were discovered to have the most consistent inhibition profile 
across multiple independent experiments (n=9-12). The dose-response curves for sulfasalazine and 
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promethazine are shown in Figure 4B. Promethazine exhibited an IC50 value of 9.83 μM (95 % confidence 
interval: 5.14-18.80 μM), while sulfasalazine proved to be a much more potent inhibitor of BCRP with an 
IC50 value of 0.79 μM (95 % confidence interval: 0.64-0.99 μM). Others have reported an IC50 of 0.6 µM for 
sulfasalazine-mediated inhibition of 
3
H-estrone-3-sulfate uptake in BCRP membrane vesicles derived from 
HEK-BCRP cells [37]. 
 
Figure 3.  MRP4 Inhibition by Aurora Kinase Inhibitors. Inhibition of MRP4-mediated [
3
H]-DHEAS (2 μM; 3.5 
min) uptake across an inhibitor concentration range of 0.316-100 μM is shown. Data are presented as mean % 
of control uptake ± SD, n=3-6 independent experiments. 
 
 
Figure 4. Characterization of the BCRP Membrane Vesicle Assay. (A) BCRP expression in MDCKII and MDCKII-
BCRP cells. Also shown is ATP-dependent, time-dependent uptake of 1 μM [
3
H]-estrone sulfate (E1S) in 
membrane vesicles. Data are presented as mean ± SD, n=3 independent experiments. (B) Dose-response IC50 
curves of the BCRP positive control inhibitors sulfasalazine and promethazine are shown (1.5 min incubation). 
Data are presented as mean % of control uptake ± SD, n=9-12 independent experiments. 
 
Of the 16 TKIs assessed, the majority (the EGFR inhibitors erlotinib, gefitinib, neratinib and vandetanib; 
the VEGFR & PDGFR inhibitors axitinib, pazopanib, sorafenib and sunitinib; the BCR/ABL inhibitors 
bosutinib, imatinib and nilotinib; and the protein kinase C isoform inhibitor enzastaurin) were found to be 
potent inhibitors of BCRP with IC50 values <10 μM (Figure 5). Notably, erlotinib, gefitinib, sorafenib, 
imatinib, nilotinib, and enzaustaurin produced IC50 values <1 μM. A previous report identified axitinib as 
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only a partial inhibitor of BCRP with an IC50 value of 4.4 μM; however the experiments were performed in 
MCDK-BCRP cell monolayers and may not be directly comparable to isolated membrane vesicle systems 
[14]. TKI inhibition potency towards BCRP was not overrepresented in one inhibitor class versus another as 
was seen for EGFR inhibitors with respect to MRP4. One TKI, lapatinib, did not produce a dose-response 
curve and was deemed to not be an inhibitor of BCRP. Dose-response curves for AKI inhibition of BCRP-
mediated transport are shown in Figure 6. In the AKI class, alisertib, barasertib, and danusertib were 
identified as potent inhibitors of BCRP with IC50 values <10 μM (Table 2). Unlike the TKIs, none of the AKIs 
produced IC50 values <1 μM and thus appeared to be slightly less potent inhibitors of BCRP. 
 
 
Figure 5. BCRP Inhibition by Tyrosine Kinase Inhibitors. Inhibition of BCRP-mediated [
3
H]-E1S (1μM; 1.5 min) 
uptake across an inhibitor concentration range of 0.00316-100 μM (0.00316-1 μM or 0.0316-10 μM for potent 
inhibitors) by EGFR, VEGFR/PDGFR, BCR/ABL inhibitors, and inhibitors with miscellaneous targets is shown. 
Data are presented as mean % of control uptake ± SD, n=3-7 independent experiments. 
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Figure 6. BCRP Inhibition by Aurora Kinase Inhibitors. Inhibition of BCRP-mediated [
3
H]-E1S (1 μM; 1.5 min) 
uptake across an inhibitor concentration range of 0.316-100 μM is shown. Data are presented as mean % of 
control uptake ± SD, n=3-4 independent experiments. 
To provide insight to the clinical relevance of TKI/AKI inhibition of MRP4- and BCRP-mediated transport, 
steady-state total plasma Css values were extracted from Micromedex and manufacturer package inserts. 
The Css values were expressed as a ratio to the IC50 for each transporter with a Css/IC50 ratio >0.1 regarded 
as having potential for clinically relevant transporter inhibition [35, 38]. Although it is well-recognized that 
drug concentrations within cells may become more concentrated than measured Css in patient plasma, 
either due to transporter-mediated accumulation or organelle binding, the use of total plasma Css values 
have been recommended and are used herein in the absence of unbound intracellular drug concentration 
data [35, 38, 39]. Css/IC50 ratios are shown in Table 2. Nine of the 20 TKI/AKIs tested exhibited Css/IC50 ratios 
>0.1 for MRP4. In particular, alisertib, danusertib, erlotinib, lapatinib, neratinib, nilotinib, pazopanib, 
sorafenib, and tozasertib were identified as having potential for clinically relevant MRP4 inhibition. 
Although the majority of potent MRP4 inhibitors (IC50 ≤ 10 μM) were found to be in the EGFR inhibitor 
class, the TKI/AKIs identified as having potential for clinical relevance were primarily stratified across both 
EGFR and Aurora kinase inhibitor classes. Only 2 VEGFR & PDGFR and 1 BCR/ABL kinase inhibitors were 
found to be clinically relevant. Similar to the report of Morgan, et al., pazopanib was identified as having 
the potential for clinically relevant MRP4 inhibition [35]. Additionally, though the studies of Morgan, et al., 
also identified gefitinib as a potent inhibitor of MRP4, gefitinib-mediated inhibition of MRP4 transport 
activity was not deemed clinically relevant [35], which is similar to the current results. The majority of the 
TKI/AKIs investigated were found to potentially be clinically relevant inhibitors of BCRP, with 15 of the 20 
compounds having a Css/IC50 ratio >0.1. Specific compounds identified were alisertib, barasertib, 
danusertib, enzastaurin, erlotinib, gefitinib, imatinib, neratinib, nilotinb, pazopanib, selumetinib, sorafenib, 
sunitinib, tozasertib, and vandetanib. Several compounds, notably alisertib, danusertib, erlotinib, neratinib, 
nilotinib, pazopanib, sorafenib, and tozasertib were found to be dual inhibitors of MRP4 and BCRP with 
potential clinical relevance for both. Dual inhibition may further complicate drug-mediated transporter 
inhibition by minimizing compensatory mechanisms for export of compounds from within a cell. In 
summation, the analysis of Css/IC50 ratios revealed a greater potential for clinically relevant BCRP inhibition 
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by TKI/AKIs compared to MRP4, though eight TKI/AKIs were found to be dual inhibitors of both 
transporters.  
Table 2. Summary of TKI and AKI Inhibition of MRP4 and BCRP. Data are presented as mean relative IC50 estimates 
(μM). Total plasma Cmax values (μM) were extracted from Micromedex 2.0 (Truven Health Analytics) and manufacturer 
package inserts. N/A = data not available. Asterisk (*) indicates Cmax/IC50 ratio >0.1 for an individual transporter. 
TKI/AKI Steady-State 
Total Css (μM) 
Mean Relative MRP4 IC50 
Estimate (μM, ±SD) 
Css/IC50 
MRP4 
Mean Relative BCRP IC50 
Estimate (μM, ±SD) 
Css/IC50 
BCRP 
Alisertib 1.80 16.54 (±4.34) 0.109* 3.00 (±0.38) 0.600* 
Axitinib 0.07 14.99 (±5.29) 0.005 1.56 (±1.07) 0.045 
Barasertib 2.30 86.30 (±81.93) 0.027 7.62 (±7.61) 0.302* 
Bosutinib 0.38 16.75 (±14.88) 0.023 9.11 (±1.81) 0.042 
Crizotinib 1.09 N/A (outside 
concentration range) 
N/A 15.90 (±8.23) 0.069 
Danusertib 9.34 8.70 (±5.18) 1.074* 7.49 (±2.70) 1.248* 
Dasatinib 0.13 18.03 (±4.42) 0.007 13.17 (±2.50) 0.010 
Enzastaurin 2.19 43.93 (±23.77) 0.050 0.97 (±0.34) 2.266* 
Erlotinib 3.95 3.11 (±1.16) 1.270* 0.11 (±0.02) 36.127* 
Gefitinib 0.43 4.48 (±1.64) 0.096 0.12 (±0.01) 3.728* 
Imatinib 2.72 N/A (partial inhibitor) N/A 0.29 (±0.15) 9.292* 
Lapatinib 4.18 8.33 (±5.68) 0.502* N/A N/A 
Neratinib 2.95 6.65 (±0.66) 0.444* 1.77 (±1.44) 1.669* 
Nilotinib 3.85 6.18 (±4.82) 0.623* 0.05 (±0.01) 81.828* 
Pazopanib 122.58 22.92 (±13.82) 5.349* 9.43 (±2.85) 13.000* 
Selumetinib 2.08 103.61 (±18.42) 0.020 15.04 (±6.21) 0.138* 
Sorafenib 21.51 2.60 (±0.33) 8.261* 0.26 (±0.08) 82.078* 
Sunitinib 0.23 91.53 (±40.46) 0.003 1.93 (±0.37) 0.119* 
Tozasertib 2.67 1.87 (±0.81) 1.427* 13.74 (±3.98) 0.194* 
Vandetanib 1.93 33.18 (±18.90) 0.058 8.70 (±3.20) 0.222* 
Conclusions 
Together, these data represent the first analysis of the inhibitory potential of multiple TKI/AKIs against 
both MRP4 and BCRP, along with estimation of the clinical relevance of TKI/AKI-facilitated transport 
inhibition. The data herein may enable greater predictive power of the pharmacokinetic/pharmacodynamic 
and potential hepatotoxic effects of TKI/AKI use in co-treatment regimens. 
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